{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:25:24Z","timestamp":1793139924954,"version":"4.5.0"},"reference-count":18,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T00:00:00Z","timestamp":1672790400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Noninvasive methods for the early identify diagnosis of prostatitis, benign prostatic hyperplasia (BPH), and prostate cancer (PCa) are current clinical challenges.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The serum metabolites of 20 healthy individuals and patients with prostatitis, BPH, or PCa were identified using untargeted liquid chromatography-mass spectrometry (LC-MS). In addition, targeted LC-MS was used to verify the organic acid metabolites in the serum of a validation cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Organic acid metabolites had good sensitivity and specificity in differentiating prostatitis, BPH, and PCa. Three diagnostic models identified patients with PROSTATITIS: phenyllactic acid (area under the curve [AUC]=0.773), pyroglutamic acid (AUC=0.725), and pantothenic acid (AUC=0.721). Three diagnostic models identified BPH: citric acid (AUC=0.859), malic acid (AUC=0.820), and D-glucuronic acid (AUC=0.810). Four diagnostic models identified PCa: 3-hydroxy-3-methylglutaric acid (AUC=0.804), citric acid (AUC=0.918), malic acid (AUC=0.862), and phenyllactic acid (AUC=0.713). Two diagnostic models distinguished BPH from PCa: phenyllactic acid (AUC=0.769) and pyroglutamic acid (AUC=0.761). Three diagnostic models distinguished benign BPH from PROSTATITIS: citric acid (AUC=0.842), ethylmalonic acid (AUC=0.814), and hippuric acid (AUC=0.733). Six diagnostic models distinguished BPH from prostatitis: citric acid (AUC=0.926), pyroglutamic acid (AUC=0.864), phenyllactic acid (AUC=0.850), ethylmalonic acid (AUC=0.843), 3-hydroxy-3-methylglutaric acid (AUC=0.817), and hippuric acid (AUC=0.791). Three diagnostic models distinguished PCa patients with PROSTATITISA &amp;lt; 4.0 ng\/mL from those with PSA &amp;gt; 4.0 ng\/mL: 5-hydromethyl-2-furoic acid (AUC=0.749), ethylmalonic acid (AUC=0.750), and pyroglutamic acid (AUC=0.929). Conclusions: These results suggest that serum organic acid metabolites can be used as biomarkers to differentiate prostatitis, BPH, and PCa.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2022.998447","type":"journal-article","created":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T14:25:01Z","timestamp":1672842301000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":23,"title":["Serum organic acid metabolites can be used as potential biomarkers to identify prostatitis, benign prostatic hyperplasia, and prostate cancer"],"prefix":"10.3389","volume":"13","author":[{"given":"Jinhua","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeping","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenfeng","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangmei","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyin","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ge","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhonghui","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuguang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanwei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,4]]},"reference":[{"key":"B1","article-title":"Correlation between prostatitis, benign prostatic hyperplasia and prostate cancer: A systematic review and meta-analysis","volume":"11","author":"Zhang","year":"2021","journal-title":"J Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s11306-011-0329-9","article-title":"Serum UPLC-MS\/MS metabolic profiling in an experimental model for acute-liver injury reveals potential biomarkers for hepatotoxicity","volume":"8","author":"Gonzalez","year":"2012","journal-title":"Metabolomics"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.4155\/bio.11.326","article-title":"Recent advances in metabolomics in oncology","volume":"4","author":"O\u2019Connell","year":"2012","journal-title":"Bioanalysis"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s11306-018-1449-2","article-title":"Review of recent developments in GC\u2013MS approaches to metabolomics-based research","volume":"14","author":"Beale","year":"2018","journal-title":"Metabolomics"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics9010021","article-title":"Metabolomics biomarkers of prostate cancer: A systematic review","volume":"9","author":"Kdadra","year":"2019","journal-title":"Diagnost (Basel Switzerland)"},{"key":"B6","doi-asserted-by":"crossref","DOI":"10.1016\/B978-0-08-100596-5.22885-0","volume-title":"Metabolomics to Study the Therapeutic Value of Natural Compounds to Treat Obesity","author":"Xu","year":"2021"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2020.06.003","article-title":"European association of urology guidelines on primary urethral carcinoma-2020 update","volume":"3","author":"Gakis","year":"2020","journal-title":"European Urology Oncology"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-06827-z","article-title":"Tumor characteristics, treatments, and survival outcomes in prostate cancer patients with a PSA level","volume":"20","author":"Zheng","year":"2020","journal-title":"BMC Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-62015-w","article-title":"Using clinical parameters to predict prostate cancer and reduce the unnecessary biopsy among patients with PSA in the gray zone","volume":"10","author":"Liu","year":"2020","journal-title":"Sci Rep"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnesp.2021.04.002","article-title":"Effect of an intensified individual nutrition therapy on serum metabolites in critically ill patients \u2013 a targeted metabolomics analysis of the ONCA study","volume":"43","author":"Gonzalez-Granda","year":"2021","journal-title":"Clin Nutr ESPEN"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s00438-019-01624-1","article-title":"Transcriptomic and metabolomic analyses reveal several critical metabolic pathways and candidate genes involved in resin biosynthesis in pinus massoniana","volume":"295","author":"Bai","year":"2020","journal-title":"Mol Genet Genomics"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/nature07762","article-title":"Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression","volume":"457","author":"Sreekumar","year":"2009","journal-title":"Nature"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.16775","article-title":"Prospective serum metabolomic profile of prostate cancer by size and extent of primary tumor","volume":"8","author":"Huang","year":"2017","journal-title":"Oncotarget"},{"key":"B14","article-title":"Prostate cancer detection in men with a \u2018normal\u2019 total prostate-specific antigen (PSA) level using percentage free PSA: A prospective screening study","volume":"95","author":"Rowe","year":"2015","journal-title":"Bju Int"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2017.08.016","article-title":"Comprehensive overview of prostatitis","volume":"94","author":"Khan","year":"2017","journal-title":"Biomed Pharmacother = Biomed Pharmacother"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s00120-020-01184-y","article-title":"Benign prostatic hyperplasia: New and treatment-relevant aspects from the DGU guidelines","volume":"59","author":"Bach","year":"2020","journal-title":"Der Urol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics11030563","article-title":"Diffusion is directional: innovative diffusion tensor imaging to improve prostate cancer detection","volume":"11","author":"Shenhar","year":"2021","journal-title":"Diagnostics (Basel, Switzerland)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/and.12265","article-title":"Presence of PSA auto-antibodies in men with prostate abnormalities (prostate cancer\/benign prostatic hyperplasia\/prostatitis)","volume":"47","author":"Lokant","year":"2015","journal-title":"Andrologia"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.998447\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T14:25:06Z","timestamp":1672842306000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.998447\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,4]]},"references-count":18,"alternative-id":["10.3389\/fimmu.2022.998447"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.998447","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,4]]},"article-number":"998447"}}